NCT04519151 2023-06-08Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian CancerSheba Medical CenterPhase 2 Recruiting24 enrolled
NCT04008082 2022-03-08A Study of Overall Survival in Participants With Unresectable Hepatocellular CarcinomaEisai Inc.Completed412 enrolled